• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Viking Therapeutics (VKTX)

Common Shares
Sell: $29.23|Buy: $29.39|Change: 0.66 (-2.20%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Address

12340 El Camino Real
Suite 250
San Diego
CA
USA
92130

Telephone

+1 858 704-4660

Website

https://www.vikingtherapeutics.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Viking Therapeutics Inc Second Quarter Earnings Conference Call for 20272027-07-29T16:30:00
Viking Therapeutics Inc Second Quarter Earnings Results for 20272027-07-29T00:00:00
Viking Therapeutics Inc Annual General Meeting for 20272027-05-19T08:00:00
Viking Therapeutics Inc First Quarter Earnings Conference Call for 20272027-04-29T16:30:00
Viking Therapeutics Inc First Quarter Earnings Results for 20272027-04-29T00:00:00
Viking Therapeutics Inc Fourth Quarter Earnings Conference Call for 20262027-02-11T16:30:00
Viking Therapeutics Inc Fourth Quarter Earnings Results for 20262027-02-11T00:00:00
Viking Therapeutics Inc Annual Report for 20262027-02-11T00:00:00
Viking Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-10-22T16:30:00
Viking Therapeutics Inc Third Quarter Earnings Results for 20262026-10-22T00:00:00

Previous key dates

NameKey Date
Viking Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-10-22T16:30:00
Viking Therapeutics Inc Third Quarter Earnings Results for 20262026-10-22T00:00:00
Viking Therapeutics - VK2735 Maintenance Study - Topline Results Webcast2026-09-22T08:00:00
Morgan Stanley 24th Annual Global Healthcare Conference2026-09-14T15:20:00
Viking Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-07-29T16:30:00
Viking Therapeutics Inc Second Quarter Earnings Result for 20262026-07-29T00:00:00
William Blair 46th Annual Growth Stock Conference2026-06-02T14:00:00
Viking Therapeutics Inc Annual General Meeting for 20262026-05-19T08:00:00
Jefferies Global Healthcare Conference2026-05-04T13:25:00
Viking Therapeutics Inc First Quarter Earnings Conference Call for 20262026-04-29T16:30:00
Viking Therapeutics Inc First Quarter Earnings Result for 20262026-04-29T00:00:00
Leerink Partners Global Healthcare Conference 20262026-03-10T10:40:00
Viking Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-11T16:30:00
Viking Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-11T00:00:00
Viking Therapeutics Inc Annual Report for 20252026-02-11T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T14:15:00
Jeeries 2025 Global Healthcare Conference2025-11-19T03:00:00
Stifel 2025 Healthcare Conference2025-11-11T16:40:00
Viking Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-10-22T16:30:00
Viking Therapeutics Inc Third Quarter Earnings Result for 20252025-10-22T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.